Comment on CMS-2026-1255-0001
American Podiatric Medical AssociationSupportAdvocacy
Summary: The American Podiatric Medical Association (APMA) supports the proposed rule to expand electronic prior authorization (ePA) capabilities, improve transparency, and establish shorter response timeframes for drug-related prior authorizations. They also advocate for clinical expertise in reviews, "gold carding" for high-performing providers, and streamlined processes for Durable Medical Equipment (DMEPOS).
The American Podiatric Medical Association (APMA) appreciates the opportunity to provide comments on CMS' proposed rule, "Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Interoperability Standards and Prior Authorization for Drugs for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, and Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges." Please find attached our formal response. If CMS has any questions or concerns, please do not hesitate to contact Gail M. Reese, JD, APMA Health Policy and Practice Director (301.581.9230 / greese@apma.org).